HYBRID EVENT: You can participate in person at Baltimore, Maryland, USA or Virtually from your home or work.
3rd Edition of
International Vaccines Congress
October 23 -25, 2023 | Boston, Massachusetts, USA
Event Book
Event program
Scientific Program
About
Magnus Group extend our heartfelt gratitude for your enthusiastic participation in the 3rd Edition of the International Vaccines Congress. (IVC 2023) was held on October 23-25, 2023 at Boston, USA. Your presence significantly contributed to the success of our event. Your insightful contributions during the sessions were invaluable and greatly enriched the discussions on crucial matters in the field of vaccines. Your passion and dedication to this important area of research were truly inspiring.
Scientific Committee Members
Joe Smyser
The Public Good Projects, United States
Sudhakar Bangera
Fellow-vaccinology managing partner AILEEN clinical research services AILEEN, India
Mayra Ramos Suzarte
Center of Molecular Immunology, CubaSpeakers
Khursheed Anwer
IMUNON, Inc., United States
Regina Au
BioMarketing Insight, United States
Joe Smyser
The Public Good Projects, United States
Kristen Lee Moriarty
UCONN Health, United States
Indira Acharya
Medstar, United States
Brandon Lucke Wold
Baylor University, United States
Paul Van Buynder
Griffith University, Australia
Levast Benoit
BIOASTER, France
Nsana Sjelin Nardiouf
Université Paris Cité, France
Daniel Becker
KyooBe Tech GmbH, Germany
Massimo Florio
University of Milan, Italy
Lev Ramirez
Universidad de La Sabana , ColombiaGallery
Vaccine Conference 2023 | Boston, USA
Pharma Conference 2019 | Paris, France
Pharma Conference 2018 | Rome, Italy
Pharmaceutics Conference 2017 | Valencia, Spain
Reviews
Pharma Conference 2018 | Rome, Italy
Pharma Conference 2017 | Valencia, Spain
Magnus Group Conferences Reveiws
Title : Vaccines and monoclonal antibodies in the prolonged treatment of non-small cell lung cancer: 20 years of follow-up
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba
Title : Observational study post emergency use authorization of itolizumab in the treatment of COVID-19
Mayra Ramos Suzarte, Center of Molecular Immunology, Cuba
Title : Purification process development of COVID antigens to identify sera needed for plasma therapy
Sushmita Koley, Senior Scientist Bio-Rad Laboratories, United States
Title : Lessons learned from the Covid-19 vaccine and what is needed when developing a vaccine for a successful rollout
Regina Au, BioMarketing Insight, United States
Title : Lessons learned for the future of social listening to address vaccine misinformation
Joe Smyser, The Public Good Projects, United States
Title : Why Low-Energy-Electron Irradiation might be a potential game changer for vaccine development, manufacturing, and pandemics prevention
Daniel Becker, KyooBe Tech GmbH, Germany